On July 3, RemeGen rose 6.93% in regular trading, trading at HK$84.25/share, with turnover of HK$168 million.

On the news front, the innovative drug sector extended its strength as dual-directory negotiations between basic medical insurance and commercial insurance entered a substantive stage, continuously catalyzing sector sentiment. A total of 557 drugs passed the basic medical insurance directory preliminary review, while 54 passed the commercial insurance innovative drug directory preliminary review. Combined with the implementation of an 8-year price protection mechanism, the payment channel has shifted toward a dual-track system of medical insurance plus commercial insurance, further expanding the commercialization potential for innovative drugs.

CITIC Construction Investment noted its optimistic outlook on innovative drug enterprises' medical insurance access and incremental commercial insurance opportunities, reinforcing the policy tailwind. Sector peers also rallied broadly, with 3SBio up 5.07%, BeiGene up 4.81%, and Akeso up 4.06%, reflecting strong industry-wide beta momentum driving the rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)